February, 2004:  Diphereline (Ipsen) launched in Serbia reaching 85% market share in GnRH prostate cancer market in 2009.  Fervex launched in Macedonia became market leader in a very crowded cold & flu market in Macedonia during the period of 2005 – 2009.

March, 2004: Deal finalized to represent Wyeth in 10 countries, including Baltics and Belarus, Ex-Yugoslavia and Albania.  Diclofenac Duo reached over 50% market share of total oral diclofenac market in Serbia, just 1.5 years after the product was launched on Serbian market.

April, 2004: PharmaSwiss launched  Tanakan® (Ipsen’s oral formulation of EGb 761) in Serbia and Montenegro.

May, 2004: PharmaSwiss AS established in Tallinn, Estonia, exclusively representing Wyeth and Whitehall.

June, 2004: PharmaSwiss Latvia SIA started its operation in Riga and UAB PharmaSwiss Lithuania in Vilnius.

September, 2004:  PharmaSwiss representative offices opened in Tirana (Albania) and Tallinn (Estonia).

December, 2004: Launch of Minirin (Desmopressin by Ferring) in Serbia and Montenegro.